Patents by Inventor Mengjun Shu

Mengjun Shu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Plants with enhanced photosynthetic efficiency and biomass yield
    Patent number: 12760319
    Abstract: The present disclosure is directed to genetically modified plants, plant cells, or plant tissues wherein the genetic modification comprises expression of an exogenous nucleic acid comprising a ribulose bisphosphate carboxylase/oxygenase large subunit-related (PRL-1) gene or homolog thereof, in the plant, plant cell, or plant tissue; and wherein the expression of the exogenous nucleic acid comprising the PRL-1 gene or homolog thereof results in enhanced photosynthetic efficiency and/or plant biomass of the plant, plant cell, or plant tissue as compared to a wild-type plant, plant cell or plant tissue without the genetic modification. Another aspect of the current disclosure is directed to methods of enhancing photosynthetic efficiency and biomass yield in a plant, plant cell, or plant tissue, the methods comprising expressing an exogenous nucleic acid comprising a PRL-1 gene or homolog thereof.
    Type: Grant
    Filed: September 29, 2023
    Date of Patent: October 13, 2026
    Assignees: 'UT-Battelle, LLC, University of Tennessee Research Foundation, The Board of Trustees of the University of Illinois
    Inventors: Wellington Muchero, Jin-Gui Chen, Biruk Ayenew Feyissa, Gerald A. Tuskan, Timothy B. Yates, Elsa De Becker, Steven J. Burgess, Stephen P. Long, Mengjun Shu
  • Mutated antibody of fully humanized HER2 antibody, and encoding gene and use thereof
    Patent number: 10253108
    Abstract: The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO: 12, SEQ ID NO: 2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: April 9, 2019
    Assignee: Genor Biopharma Co., Ltd.
    Inventors: Qing Zhou, Mengjun Shu, Zhuzi He, Jun Lin
  • MUTATED ANTIBODY OF FULLY HUMANIZED HER2 ANTIBODY, AND ENCODING GENE AND USE THEREOF
    Publication number: 20170037146
    Abstract: The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO:12, SEQ ID NO:2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.
    Type: Application
    Filed: December 8, 2015
    Publication date: February 9, 2017
    Applicant: Genor Biopharma Co., Ltd
    Inventors: Qing Zhou, Mengjun Shu, Zhuzi He, Jun Lin